Moreover, the 36-month beta value for CVKD is 1.87. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CVKD is 8.48M and currently, short sellers hold a 0.50% of that float. On April 18, 2024, CVKD’s average trading volume was 462.84K shares.
CVKD) stock’s latest price update
Cadrenal Therapeutics Inc (NASDAQ: CVKD)’s stock price has gone rise by 8.16 in comparison to its previous close of 0.39, however, the company has experienced a -4.66% decrease in its stock price over the last five trading days. PRNewsWire reported 2023-10-09 that PONTE VEDRA, Fla., Oct. 9, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham, CEO, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023.
CVKD’s Market Performance
Cadrenal Therapeutics Inc (CVKD) has experienced a -4.66% fall in stock performance for the past week, with a -24.70% drop in the past month, and a -49.79% drop in the past quarter. The volatility ratio for the week is 11.12%, and the volatility levels for the past 30 days are at 11.61% for CVKD. The simple moving average for the past 20 days is -23.23% for CVKD’s stock, with a -44.54% simple moving average for the past 200 days.
Analysts’ Opinion of CVKD
Many brokerage firms have already submitted their reports for CVKD stocks, with Noble Capital Markets repeating the rating for CVKD by listing it as a “Outperform.” The predicted price for CVKD in the upcoming period, according to Noble Capital Markets is $4 based on the research report published on December 18, 2023 of the previous year 2023.
CVKD Trading at -38.34% from the 50-Day Moving Average
After a stumble in the market that brought CVKD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.57% of loss for the given period.
Volatility was left at 11.61%, however, over the last 30 days, the volatility rate increased by 11.12%, as shares sank -26.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -69.78% lower at present.
During the last 5 trading sessions, CVKD fell by -5.04%, which changed the moving average for the period of 200-days by -72.19% in comparison to the 20-day moving average, which settled at $0.5418. In addition, Cadrenal Therapeutics Inc saw -43.01% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CVKD starting from MURPHY JOHN RAYMOND, who purchase 2,669 shares at the price of $0.69 back on Oct 05 ’23. After this action, MURPHY JOHN RAYMOND now owns 614,792 shares of Cadrenal Therapeutics Inc, valued at $1,842 using the latest closing price.
MURPHY JOHN RAYMOND, the Director of Cadrenal Therapeutics Inc, purchase 17,331 shares at $0.70 during a trade that took place back on Oct 04 ’23, which means that MURPHY JOHN RAYMOND is holding 612,123 shares at $12,132 based on the most recent closing price.
Stock Fundamentals for CVKD
The total capital return value is set at -0.99. Equity return is now at value -780.59, with -179.77 for asset returns.
Based on Cadrenal Therapeutics Inc (CVKD), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -165.35. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -446.34.
Currently, EBITDA for the company is -7.63 million with net debt to EBITDA at 1.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.27.
Conclusion
To wrap up, the performance of Cadrenal Therapeutics Inc (CVKD) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
